New $59 million Ixiaro contract with US government for Valneva

16 January 2019

French biotech firm Valneva (Euronext: VLA), a leading pure play vaccine company, today announced the signing of a new contract with the US government Department of Defense for the supply of its Japanese encephalitis (JE) vaccine Ixiaro, with the news sending the firm’s shares up 6.9% to 3.70 euros.

Under the terms of the agreement, Valneva will supply Ixiaro doses to the Defense Logistics Agency of the US Department of Defense, through 2019 and the beginning of 2020 with a value of $59 million guaranteed and potentially worth up to $70 million. A delivery schedule is being prepared and supply shipments will commence immediately.

“We are pleased to continue our important collaboration with the US government to fight this deadly disease. The US military has been using Ixiaro since 2010 and we are excited to further support the expansion of its use and help protect military personnel and their families from Japanese encephalitis,” commented Valneva’s chief business officer Franck Grimaud.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK